TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers at the University Hospital of Bonn and the University of Bonn directly converted human red blood cell precursors into neural stem cells in a laboratory. The process gradually reset epigenetic age markers, with cells from an 80-year-old measured at under 20 years by the study’s molecular clock; the work does not show that people have been rejuvenated or that a treatment is available.
Researchers at the University Hospital of Bonn and the University of Bonn have converted human red blood cell precursors directly into neural stem cells in laboratory experiments, while tracking a gradual reset in markers of cellular age. In one reported example, cells from an 80-year-old donor had an epigenetic-clock reading of less than 20 years after reprogramming; the finding is about cells in a test tube, not a demonstrated rejuvenation treatment for people.
The team used transcription factors—proteins that affect which genetic instructions a cell reads—to redirect blood-cell precursors toward a neural stem-cell identity. The resulting cells can give rise to neurons. The researchers reported that the conversion also changed DNA modifications used by epigenetic clocks to estimate a cell’s molecular age. These markers do not alter the underlying DNA sequence.
The study’s key distinction is that the cells were converted directly into neural stem cells, rather than first being turned into pluripotent stem cells, which can develop into many cell types, and then guided toward a neural fate. According to the report, the direct method took place gradually, allowing the team to follow the clock changes over more than 100 days. A separate description of the findings says cells had become 60 years younger after 50 days; the clock-based age figures are measurements of cellular markers, not evidence that a donor’s body or health became younger.
The findings were published in Aging Cell as “Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells.” The paper lists L. J. Berg and colleagues as authors. The report attributes the research to Bonn’s Institute of Reconstructive Neurobiology, led by Prof. Oliver Brüstle.
A Model for Studying Cellular Age
The result matters primarily as a research method. Because the measured age markers changed over weeks rather than being reset rapidly in a two-stage process, researchers may be able to examine which factors speed up or slow down epigenetic change while cells acquire a new identity. That could help clarify how cellular reprogramming works and how age-related changes relate to neural cells.
Brüstle told News-Medical that age is the most important risk factor for neurodegenerative diseases such as Alzheimer’s. That statement explains the team’s interest in the field, but the experiment does not show that the converted cells prevent, treat or reverse Alzheimer’s or other disease. The work offers a laboratory model for investigation, not evidence of a clinical benefit.
The distinction is important for readers considering claims about “rejuvenation.” The reported result concerns an epigenetic age estimate in reprogrammed cells. It does not establish that all features of aging were reversed, that the cells function like young cells in a person, or that the procedure is safe or effective as a therapy.
As an affiliate, we earn on qualifying purchases.
Direct Conversion Versus Two Steps
Cells in the body share genetic material but take on different roles as they develop. In ordinary conditions, a blood cell does not naturally become a neuron. Laboratory reprogramming uses transcription factors to alter the cell’s developmental path. Researchers can make neural tissue from other cell types, including skin cells, although that possibility alone does not establish a medical use.
Earlier work had found that epigenetic age markers can reset during reprogramming that passes through a pluripotent stem-cell stage before producing neural stem cells. The Bonn team’s approach bypassed that intermediate stage. It reported a slower, more trackable change during direct conversion, which the researchers say could make the method useful for studying the process over time.
The Bonn researchers had also previously reported that nerve cells produced through their reprogramming work formed connections with existing neurons after transplantation into mouse brains. That prior result is a separate line of research: it does not mean the current study tested a human treatment or demonstrated benefit in patients.
“We have directly converted red blood cell precursors into neural stem cells.”
— Prof. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University Hospital of Bonn
As an affiliate, we earn on qualifying purchases.
What the Age Reading Does Not Show
The report does not provide enough detail to establish how many donors or cell samples were included, how consistently the age-marker reset occurred, or how the converted cells performed across a wider range of tests. The age of less than 20 years is an epigenetic-clock measurement; it should not be read as proof that every aspect of a cell’s aging was reversed.
It is also unclear from the supplied report whether the converted cells retain their new identity and function over the long term, or how the procedure might affect safety. The researchers did not report a human trial. The work therefore does not show that the method can rejuvenate tissues in the body, extend life, or prevent or treat neurodegenerative disease.
As an affiliate, we earn on qualifying purchases.
Further Tests of the Reprogramming Process
The researchers say the slowly changing epigenetic clocks can be used to investigate biological factors and active substances that may alter the pace of reprogramming. The next scientific questions include which mechanisms drive the age-marker changes, whether the results are reproducible across more samples, and how the resulting neural stem cells behave over time.
The study is a starting point for laboratory research, not a stated clinical program. The supplied report does not give a timetable for follow-up studies or announce plans to test the method in people. Any future therapeutic use would require further evidence on cell identity, function and safety before its relevance to patients could be assessed.
laboratory stem cell culture supplies
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Bonn researchers do?
They directly reprogrammed human red blood cell precursors into neural stem cells in laboratory experiments and tracked changes in epigenetic age markers during the process.
Were the donors or patients rejuvenated?
No. The reported age shift refers to cells measured in a laboratory, not a change in a donor’s age, health or body. The report does not describe a treatment given to people.
What does an epigenetic-clock reading measure?
It estimates cellular age from patterns of DNA modifications associated with aging. These modifications affect how genetic information is read, but the clock reading is not a direct measure of a person’s age or overall health.
Why is the direct method of interest?
Unlike a two-step process that passes through a pluripotent stem-cell stage, the Bonn approach went directly from blood-cell precursors to neural stem cells. The reported gradual change over more than 100 days may give researchers time to study the process.
Could this lead to an Alzheimer’s treatment?
The study does not show that the method treats or prevents Alzheimer’s. The researchers describe a potential laboratory model for studying age-related cellular changes; clinical benefit remains unproven.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
